Tonsillitis Treatment Market Highlights 2022 – 2030
The tonsillitis treatment market is estimated to garner a hefty amount of revenue by growing at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the rising incidences of flu around the world and high germ exposure of people living in under-developed nations. On an average, in the United States, 5% to 20% of the population gets the flu. The disease results in more than 32 million people outpatient visits each year. Along with these, growing prevalence of infections caused by virus and bacteria, detrimental changes in the lifestyle and increasing shift towards unhealthy eating habits among people are also expected to drive market growth in the near future. Furthermore, escalating government initiatives to spread awareness about antibiotic and over-the-counter treatment in rural and semi-urban areas is projected to provide ample growth opportunities to the market in the forthcoming years.
The market is segmented by treatment into antibiotics, over-the-counter drugs, homeopathy medicines, tonsillectomy and others, out of which, the antibiotics segment is anticipated to hold the largest share in the tonsillitis treatment market on account of the characteristics of these drugs such as slowing down infection growth, speedy recovery, prevention of occurrence of infection and ease of consumption. According to the Centers for Disease Control and Prevention (CDC), 266.1 million courses of antibiotics are dispersed to outpatients in U.S. community pharmacies. Moreover, the segment for over-the-counter drugs is predicted to witness noteworthy growth over the forecast period, which can be credited to the increasing usage of these medication for treating ailments in children and young teenagers. Apart from these, the effectiveness of these medication in relieving symptoms caused by viral infections are also assessed to fuel the growth of this market segment in the future.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Tonsillitis Treatment Market Regional Synopsis
On the basis of geographical analysis, the tonsillitis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in North America region is estimated to occupy the largest share over the forecast period on the back of presence of well-established healthcare facilities, major market players and high levels of awareness regarding different medications in the region. In addition to these, high government spending on the healthcare sector is also expected to fuel the region’s market growth in the coming years. Moreover, the market in Asia Pacific is anticipated to witness noteworthy growth during the forecast period, which can be ascribed to the large patient pool, improper maintenance of cleanliness in South Asian countries and increasing private investments for establishment of hospitals in the region. As per a report by UNICEF, India accounted for 90% of the people in South Asia and 1.2 billion people in the world that defecated in the open. This situation contributed to the deaths of 100,000 children under five years in the country.
The tonsillitis treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the tonsillitis treatment market includes the following segments:
By Disease Type
- Acute
- Recurrent
- Chronic
By Disease Cause
- Bacteria
- Virus
By Treatment
- Antibiotics
- Over-the-Counter Drugs
- Homeopathy Medicines
- Tonsillectomy
- Others
Growth Drivers
- Increasing Number of Incidences of Flu Around the World
- High Germ Exposure of People in Under Developed Nations
Challenges
- Lack of Regulations for the Certification of Medications in Lower Income Economies
Top Featured Companies Dominating the Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Reckitt Benckiser Group plc
- Sun Pharmaceutical Industries Ltd
- Bayer AG
- AstraZeneca plc
- Novartis AG
- Walgreen Co.
- Prestige Brands Holdings, Inc
- Perrigo Company
